Who makes MD Sing2016 M2SR H3N2 influenza vaccine?

MD Sing2016 M2SR H3N2 influenza vaccine is developed by FluGen Inc.

What development phase is MD Sing2016 M2SR H3N2 influenza vaccine in?

MD Sing2016 M2SR H3N2 influenza vaccine is in Phase 1.

What are the side effects of MD Sing2016 M2SR H3N2 influenza vaccine?

Common side effects include fatigue, headache, nasal congestion, cough, myalgia, rhinorrhea.

Last reviewed 2026-04-20 · How we verify

MD Sing2016 M2SR H3N2 influenza vaccine

FluGen Inc · Phase 1 active Biologic Quality 15/100

At a glance

Generic name	MD Sing2016 M2SR H3N2 influenza vaccine
Sponsor	FluGen Inc
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

fatigue
headache
nasal congestion
cough
myalgia
rhinorrhea
throat irritation
arthralgia
pyrexia
oropharyngeal pain
nausea
nasal discomfort

Key clinical trials

Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MD Sing2016 M2SR H3N2 influenza vaccine CI brief — competitive landscape report
MD Sing2016 M2SR H3N2 influenza vaccine updates RSS · CI watch RSS
FluGen Inc portfolio CI